S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Asian markets sink, with Japan’s Nikkei down 3.5%, as Mideast tensions flare
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Asian markets sink, with Japan’s Nikkei down 3.5%, as Mideast tensions flare
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Asian markets sink, with Japan’s Nikkei down 3.5%, as Mideast tensions flare
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Asian markets sink, with Japan’s Nikkei down 3.5%, as Mideast tensions flare
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
American Renal Associates Holdings, Inc. stock logo
ARA
American Renal Associates
$11.52
$11.50
$5.57
$11.98
$397.94M1.11106,940 shs9,831 shs
Baudax Bio, Inc. stock logo
BXRX
Baudax Bio
$0.02
+7.4%
$0.02
$0.01
$3.47
$1.14M1.57281,029 shs310,800 shs
HemaCare Co. stock logo
HEMA
HemaCare
$25.31
+0.6%
$25.31
$8.62
$26.23
$346.52M1.4739,950 shs5,400 shs
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
American Renal Associates Holdings, Inc. stock logo
ARA
American Renal Associates
0.00%0.00%0.00%0.00%0.00%
Baudax Bio, Inc. stock logo
BXRX
Baudax Bio
0.00%0.00%0.00%-12.80%-99.08%
HemaCare Co. stock logo
HEMA
HemaCare
0.00%0.00%0.00%0.00%0.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
American Renal Associates Holdings, Inc. stock logo
ARA
American Renal Associates
N/AN/AN/AN/AN/AN/AN/AN/A
Baudax Bio, Inc. stock logo
BXRX
Baudax Bio
N/AN/AN/AN/AN/AN/AN/AN/A
HemaCare Co. stock logo
HEMA
HemaCare
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
American Renal Associates Holdings, Inc. stock logo
ARA
American Renal Associates
N/AN/AN/AN/A
Baudax Bio, Inc. stock logo
BXRX
Baudax Bio
N/AN/AN/AN/A
HemaCare Co. stock logo
HEMA
HemaCare
N/AN/AN/AN/A

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
American Renal Associates Holdings, Inc. stock logo
ARA
American Renal Associates
$822.52M0.48$1.69 per share6.80$2.59 per share4.45
Baudax Bio, Inc. stock logo
BXRX
Baudax Bio
$1.27M0.90N/AN/A($14.93) per share0.00
HemaCare Co. stock logo
HEMA
HemaCare
N/AN/AN/AN/AN/AN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
American Renal Associates Holdings, Inc. stock logo
ARA
American Renal Associates
-$13.79M$0.26N/AN/AN/A-2.04%-3.56%-0.24%N/A
Baudax Bio, Inc. stock logo
BXRX
Baudax Bio
-$58.79M-$9.23N/AN/AN/AN/AN/A-175.11%5/10/2024 (Estimated)
HemaCare Co. stock logo
HEMA
HemaCare
N/AN/A0.00N/AN/AN/AN/AN/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
American Renal Associates Holdings, Inc. stock logo
ARA
American Renal Associates
N/AN/AN/AN/AN/A
Baudax Bio, Inc. stock logo
BXRX
Baudax Bio
N/AN/AN/AN/AN/A
HemaCare Co. stock logo
HEMA
HemaCare
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
American Renal Associates Holdings, Inc. stock logo
ARA
American Renal Associates
7.54
1.05
1.02
Baudax Bio, Inc. stock logo
BXRX
Baudax Bio
N/A
0.07
0.07
HemaCare Co. stock logo
HEMA
HemaCare
N/AN/AN/A

Ownership

Institutional Ownership

CompanyInstitutional Ownership
American Renal Associates Holdings, Inc. stock logo
ARA
American Renal Associates
78.42%
Baudax Bio, Inc. stock logo
BXRX
Baudax Bio
9.05%
HemaCare Co. stock logo
HEMA
HemaCare
N/A

Insider Ownership

CompanyInsider Ownership
American Renal Associates Holdings, Inc. stock logo
ARA
American Renal Associates
9.50%
Baudax Bio, Inc. stock logo
BXRX
Baudax Bio
0.10%
HemaCare Co. stock logo
HEMA
HemaCare
26.20%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
American Renal Associates Holdings, Inc. stock logo
ARA
American Renal Associates
4,97734.54 millionN/AOptionable
Baudax Bio, Inc. stock logo
BXRX
Baudax Bio
952.46 million52.41 millionNot Optionable
HemaCare Co. stock logo
HEMA
HemaCare
N/A13.69 millionN/ANot Optionable

HEMA, ARA, and BXRX Headlines

SourceHeadline
Donors flock to blood centers following Union Station shootingDonors flock to blood centers following Union Station shooting
msn.com - February 21 at 11:59 PM
Leukapheresis Market size worth $ 100647.54 Million, Globally, by 2028 at 6.08% CAGR: Verified Market Research®Leukapheresis Market size worth $ 100647.54 Million, Globally, by 2028 at 6.08% CAGR: Verified Market Research®
prnewswire.co.uk - November 7 at 12:50 PM
HEMA Historical DataHEMA Historical Data
investing.com - October 22 at 8:02 PM
Plasmapheresis Periprocedural Care Equipments Market Is Likely to Grasp the CAGR of 5.20% By 2029Plasmapheresis Periprocedural Care Equipments Market Is Likely to Grasp the CAGR of 5.20% By 2029
pharmiweb.com - October 3 at 1:05 PM
Primary Cells Market worth $2.8 billion | MarketsandMarketsPrimary Cells Market worth $2.8 billion | MarketsandMarkets
finanznachrichten.de - July 6 at 12:35 PM
The worldwide Therapeutic Plasma Exchange industry is currently experiencing significant growth and expanding at a 13.6% CAGR from 2023 - 2030The worldwide Therapeutic Plasma Exchange industry is currently experiencing significant growth and expanding at a 13.6% CAGR from 2023 - 2030
marketwatch.com - June 22 at 8:29 PM
Powering Hope: Bone Marrow Transplantation Market Set to Grow at a Robust CAGR of 3.7% through 2023-2028| HemaCare, ReeLabs Pvt. Ltd.Powering Hope: Bone Marrow Transplantation Market Set to Grow at a Robust CAGR of 3.7% through 2023-2028| HemaCare, ReeLabs Pvt. Ltd.
medgadget.com - June 7 at 2:40 PM
Primary Hepatocytes Market Set to Skyrocket with a Staggering CAGR of 6.6% by 2023-2032| Lonza, Corning Inc.Primary Hepatocytes Market Set to Skyrocket with a Staggering CAGR of 6.6% by 2023-2032| Lonza, Corning Inc.
medgadget.com - June 6 at 6:38 PM
Region-Wise Apheresis Machines Market Analysis Forecast 2023-2030Region-Wise Apheresis Machines Market Analysis Forecast 2023-2030
marketwatch.com - May 16 at 8:20 AM
2023 Apheresis Machines Market Price & News with Size Forecast 20302023 Apheresis Machines Market Price & News with Size Forecast 2030
marketwatch.com - May 14 at 8:34 AM
Peripheral Blood Market upto 2030Peripheral Blood Market upto 2030
marketwatch.com - May 14 at 1:11 AM
2023 Bone Marrow Transplant Market: Trends and Forecast 2031 | A Detailed Sales Channel Analysis Report2023 Bone Marrow Transplant Market: Trends and Forecast 2031 | A Detailed Sales Channel Analysis Report
marketwatch.com - May 9 at 12:43 AM
Research Use Human Cells Market 2023 Size, Status and Global Outlook -Charles River, Lonza, Thermo Fisher Scientific, Sigma-AldrichResearch Use Human Cells Market 2023 Size, Status and Global Outlook -Charles River, Lonza, Thermo Fisher Scientific, Sigma-Aldrich
marketwatch.com - May 4 at 3:19 AM
Apheresis Equipment Market Size 2023, Industry Share, Growth, Trends, Revenue Analysis 2023-2030Apheresis Equipment Market Size 2023, Industry Share, Growth, Trends, Revenue Analysis 2023-2030
marketwatch.com - May 3 at 5:17 PM
Bone Marrow Transplant Market Growth Opportunities and Emerging Trends till 2031Bone Marrow Transplant Market Growth Opportunities and Emerging Trends till 2031
marketwatch.com - May 3 at 12:17 PM
Apheresis Devices Market Complete Overview till 2031Apheresis Devices Market Complete Overview till 2031
marketwatch.com - April 28 at 9:07 PM
Global Continuous Flow Apheresis Device Market Growth, Size and Manufacturers Analysis Research Report and Forecast 2023-2030 By VMReportsGlobal Continuous Flow Apheresis Device Market Growth, Size and Manufacturers Analysis Research Report and Forecast 2023-2030 By VMReports
marketwatch.com - April 15 at 10:45 PM
Peripheral Blood Market Forecasted from 2023-2030Peripheral Blood Market Forecasted from 2023-2030
marketwatch.com - April 13 at 1:51 PM
Navigating the Pharmaceutical Sterility Testing Market Growth Outlook by market Trends and market size Using a 6.9% CAGR from 2023 - 2030Navigating the Pharmaceutical Sterility Testing Market Growth Outlook by market Trends and market size Using a 6.9% CAGR from 2023 - 2030
marketwatch.com - April 10 at 11:57 PM
Leukapheresis Market | Extensive Growth by 2031Leukapheresis Market | Extensive Growth by 2031
marketwatch.com - April 6 at 8:06 AM
Bone Marrow Transplant Market 2023 Size and Forecast to 2031Bone Marrow Transplant Market 2023 Size and Forecast to 2031
marketwatch.com - April 4 at 8:28 AM
Apheresis Machines Market Growth and Forecast till 2030Apheresis Machines Market Growth and Forecast till 2030
marketwatch.com - March 28 at 8:56 AM
Therapeutic Plasma Exchange Market Size By 2031Therapeutic Plasma Exchange Market Size By 2031
marketwatch.com - March 24 at 1:32 AM
Apheresis Devices Market Growth and Forecast till 2028Apheresis Devices Market Growth and Forecast till 2028
marketwatch.com - March 23 at 10:31 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

American Renal Associates logo

American Renal Associates

NYSE:ARA
American Renal Associates Holdings, Inc. operates as a dialysis services provider in the United States. It operates dialysis clinics focusing on joint venture partnerships with physicians. The company offers kidney dialysis services to patients suffering from chronic kidney failure or end stage renal disease. As of December 31, 2019, it operated 246 dialysis clinics in partnership with 400 nephrologist partners treating approximately 17,300 patients in 27 states and the District of Columbia. The company was founded in 1999 and is headquartered in Beverly, Massachusetts.
Baudax Bio logo

Baudax Bio

NASDAQ:BXRX
Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care related settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with other non-NSAID analgesics. It also develops BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMB, which is in phase I clinical trial, as well as a proprietary blockade reversal agent; and BX3000, a NMB reversal agent that is in preclinical studies. Baudax Bio, Inc. was incorporated in 2019 and is based in Malvern, Pennsylvania.
HemaCare logo

HemaCare

OTCMKTS:HEMA
HemaCare Corporation provides human-derived primary blood cells and tissues for biomedical research, and supporting cell therapy clinical trials and commercialization with apheresis collections in the United States. The company specializes in the customized collection, isolation, and testing of primary human blood cells and other biological products for research protocols and cellular therapy. It offers human blood cellular components derived from peripheral blood, bone marrow, and cord blood; and a range of consulting services in standard operating procedure development, personnel training, and quality and regulatory compliance. The company's network of FDA-registered, GMP/GTP-compliant collection centers ensures donor materials available to customers, as well as for use within its isolation laboratory. The company has strategic partnership with Charles River Laboratories International Inc. for human immune system research. HemaCare Corporation was founded in 1978 and is headquartered in Northridge, California.